Prestige Consumer Healthcare stock falls after sharp drop toward 52-week low

Prestige Consumer Healthcare Inc stock (ISIN US74116D1037) traded around USD 44.95 on the New York Stock Exchange as of September 19, 2026, down roughly 3.4 percent from the prior close and hovering close to its 52-week low in a volatile year for the shares.

Stock under pressure near 52-week low

According to a balance-sheet and quote overview on a Reuters financials page for PBH as of September 19, 2026, the stock was last quoted at about USD 44.95, with a daily move of minus 1.59 USD or around minus 3.41 percent from the previous trading day, based on delayed data for the primary US listing on the New York Stock Exchange.

The same overview indicates a 52-week trading range of roughly USD 43.05 to USD 70.96, meaning the current price is only about USD 1.90 above the 52-week low and almost USD 26.00 below the 52-week high, underlining how far Prestige Consumer Healthcare stock has retreated from last year’s peak.

Valuation gap emerges against fair-value estimate

As a cross-check on valuation, an analysis note on September 18, 2026 from GuruFocus reported that Prestige Consumer Healthcare shares fell 3.2 percent on that day to USD 44.97 and are trading at a substantial discount to a model-based fair-value estimate.GuruFocus According to this valuation overview on September 18, 2026, the platform’s GF Value estimate for PBH stands at USD 71.99, implying that at the USD 44.97 price mark the shares were trading about 37.5 percent below that fair-value level.

In the same note, the GF Score for Prestige Consumer Healthcare is cited at 65 out of 100, which the portal characterizes as an above-average rating in its internal scoring system, suggesting that the company’s fundamentals and profitability profile remain solid even as the market price has corrected sharply from earlier highs.GuruFocus For investors, the key takeaway from this comparison is that the shares have moved from near the top of their 52-week band to a level more than one-third below a model fair value within the span of the last year.

Recent moves frame risk and opportunity

When the current quote around USD 44.95 on September 19, 2026 is set against the GF Value estimate of USD 71.99 reported in the same GuruFocus piece dated September 18, 2026, the discount remains roughly in the high-30-percent range, reflecting continued skepticism or caution in the market despite the above-average GF Score profile.GuruFocus This combination of a price near the 52-week low and a sizeable gap to a fair-value assessment puts Prestige Consumer Healthcare stock into a classic value-versus-risk discussion.

While the recent analysis underlines that the company still scores reasonably well on composite fundamental metrics, the price performance over the past 52 weeks shows that the stock has fallen from a high near USD 70.96 down to the mid-USD 40 range, a swing of more than USD 25.00 per share that long-term holders must now weigh against their expectations for future earnings and cash flows.

Prestige Consumer Healthcare stock price and market data

Per the latest multi-source data snapshot for the New York Stock Exchange listing, Prestige Consumer Healthcare stock is trading at approximately USD 44.95 on September 19, 2026, with that price sitting just above the 52-week low of about USD 43.05 and well below the 52-week high of roughly USD 70.96, underscoring the scale of the drawdown over the last year.

More news and analyses on Prestige Consumer Healthcare stock